On October 13, 2016, Technical Communications Corporation received an order valued at approximately $2,373,000 from Datron World Communications, Inc., for our military-grade DSP 9000 radio encryption equipment.
Unusual 11 Mid-Day Movers 10/19: (TCCO) (CERU) (BANC) Higher; (PBYI) (VDSI) (IMPV) Lower
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Cerulean Pharma Inc. (Nasdaq: CERU) 40.0% HIGHER; announced that the Company has entered into a strategic collaboration with Novartis to develop NDC product candidates combining Cerulean’s proprietary Dynamic Tumor Targeting technology with Novartis’ proprietary compounds directed at up to five targets. The company also announced that it has entered into a $20 million common stock purchase agreement (Purchase Agreement) and a registration rights agreement (Registration Rights Agreement) with Aspire Capital Fund, LLC (Aspire), a Chicago-based institutional investor. These agreements constitute a firm commitment at-the-market equity facility. Immediately following the execution of the Purchase Agreement, Aspire purchased 800,000 shares of common stock for $1.25 per share.
Puma Biotechnology, Inc. (NYSE: PBYI) 17.1% LOWER; announced that it is commencing an underwritten public offering of $150 million of shares of its common stock. Puma Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. All of the shares are being offered by Puma Biotechnology.
Banc of California (NYSE: BANC) 17.0% HIGHER; reported Q3 EPS of $0.59, $0.17 better than the analyst estimate of $0.42. BofC also announced that Seeking Alpha commented on a previous financial blog post regarding the Company. At 8:54 a.m. ET, Seeking Alpha admitted, "This item was posted as an instablog, which is not subject to editorial approval." Four minutes later, Seeking Alpha posted an update to the story, acknowledging that a government investigation "showed the shady Jason Galanis fabricated his connections to bank CEO Steven Sugarman's COR Capital."
VASCO Data Security International, Inc. (Nasdaq: VDSI) 15.4% LOWER; announced preliminary results for the third quarter ended September 30, 2016. Total revenue in the range of $42 million to $44 million and non-GAAP net income from continuing operations1 of $0.07 to $0.09 per fully diluted share. (The Street sees Q3 revenue of $52.5 million and EPS of $0.04.)
Imperva (NYSE: IMPV) 14.4% LOWER; lower following news that its sales process is on hold.
XOMA (Nasdaq: XOMA) 14.3% LOWER; announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company’s proposal to initiate a multi-dose Phase 2 clinical study of XOMA 358 in children two years and older diagnosed with Congenital Hyperinsulinism (CHI).
GNC Holdings (NYSE: GNC) 13.0% HIGHER; active following news that the company met with a range of Chinese buyers in recent weeks to gauge interest in a potential buyout.
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) 12.6% HIGHER; RTTR shares continuing higher from earlier in the week after announcing that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.
WSI Industries (Nasdaq: WSCI) 12.0% LOWER; reported Q4 EPS of ($0.01), versus $0.01 reported last year. Revenue for the quarter came in at $8.11 million, versus $8.8 million reported last year.
iPass Inc. (Nasdaq: IPAS) 11.7% HIGHER; Maxim Group initiated coverage on iPass with a Buy rating and a price target of $3.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 01/19: (CSX) (OCLR) (NFLX) Higher; (AMDA) (DRYS) (RCII) Lower (more...)
- Interpace Diagnostics (IDXG) Enters $4M Common Stock Securities Purchase Agreement
- After-Hours Stock Movers 01/12: (P) (NVLS) Higher; (WPX) (TWO) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesMaxim Group, Unusual 11 Mid-Day Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!